Updated on 12 June 2013
Why should a big pharmaceutical company be interested in integrating Linguet into their drug delivery mechanism?
Imugene takes existing drugs, with known and established safety and efficacy profiles, and reformulates them into improved products. This helps avoid excess time, risk and cost associated with the traditional new drug discovery and development process.
It is of interest to the pharmaceutical companies, that are losing market share due to loss of patent, to regain the market position using an enhanced drug delivery technology. This would also protect the company against future generic competition and significantly extend the life-cycle management of its successful product. We view companies such as Novartis, GSK, Teva Pharmaceuticals as potential acquirers of Imugene‘s technology.
Which drugs are currently being reformulated by Imugene and what are the costs involved?
Imugene has invested $2 million in the new technology, which has resulted in two patents and positive clinical results for Linguet formulations of naproxen (Naprogesic) and ibuprofen (Nurofen). Imugene, in collaboration and deal opportunities with big pharmaceutical companies, has selected three large initial targets in the areas of vitamin D deficiency, over-the-counter pain relief medication and Parkinson's Disease.